The role of cyclic adenosine 3',5'-monophosphate and polyol metabolism in diabetic neuropathy.
The effects of a stable prostacyclin analog, Iloprost, and aldose reductase inhibitors (ONO-2235 and isoliquiritigenin) were studied to elucidate the role of cAMP in diabetic neuropathy in relation to polyol metabolism. In in vivo experiments, the cAMP and myoinositol contents in sciatic nerves and motor nerve conduction velocity were significantly reduced in diabetic rats. Iloprost significantly restored the reduced cAMP content in sciatic nerves and improved motor nerve conduction velocity in diabetic rats. However, the contents of sorbitol or myoinositol in sciatic nerves were not affected by Iloprost in diabetic rats. On the other hand, aldose reductase inhibitors significantly reduced the sorbitol content and increased the cAMP and myoinositol contents in the sciatic nerves of diabetic rats. The motor nerve conduction velocity was also slightly but significantly improved by treatment with aldose reductase inhibitors. There was a negative correlation between cAMP and sorbitol in the sciatic nerves of diabetic rats treated with aldose reductase inhibitors and a positive correlation between cAMP and motor nerve conduction velocity. In in vitro experiments, Iloprost significantly increased cAMP, but did not affect the sorbitol content in sciatic nerves. Aldose reductase inhibitors inhibited sorbitol accumulation and increased cAMP in sciatic nerves. Our data suggest that polyol pathway activation somehow results in cAMP reduction in sciatic nerves and that the reduction of cAMP in peripheral nerves may be closely related to the pathogenesis of diabetic neuropathy.
Shindo
H
H
Third Department of Internal Medicine, University of Yamanashi Medical School, Japan.
Tawata
M
M
Aida
K
K
Onaya
T
T
D000449:Aldehyde Reductase / Q000037:antagonists & inhibitors*; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D002599:Chalcone / Q000031:analogs & derivatives* / Q000627:therapeutic use; D047188:Chalcones; D000242:Cyclic AMP / Q000378:metabolism*; D006152:Cyclic GMP / Q000378:metabolism; D003921:Diabetes Mellitus, Experimental / Q000378:metabolism / Q000503:physiopathology*; D003929:Diabetic Neuropathies / Q000188:drug therapy / Q000378:metabolism / Q000503:physiopathology*; D016285:Iloprost / Q000627:therapeutic use*; D007294:Inositol / Q000378:metabolism*; D008297:Male; D009431:Neural Conduction / Q000187:drug effects*; D051381:Rats; D011921:Rats, Inbred WKY; D012236:Rhodanine / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D012584:Sciatic Nerve / Q000187:drug effects / Q000378:metabolism / Q000503:physiopathology*; D013012:Sorbitol / Q000378:metabolism*; D053778:Thiazolidines
D001786:Blood Glucose; D047188:Chalcones; D053778:Thiazolidines; C038131:epalrestat; D007294:Inositol; D013012:Sorbitol; D002599:Chalcone; D012236:Rhodanine; C040920:isoliquiritigenin; D000242:Cyclic AMP; D000449:Aldehyde Reductase; D006152:Cyclic GMP; D016285:Iloprost